These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 26713839

  • 1. In Vitro and in Vivo Characterization of MOD-4023, a Long-Acting Carboxy-Terminal Peptide (CTP)-Modified Human Growth Hormone.
    Hershkovitz O, Bar-Ilan A, Guy R, Felikman Y, Moschcovich L, Hwa V, Rosenfeld RG, Fima E, Hart G.
    Mol Pharm; 2016 Feb 01; 13(2):631-9. PubMed ID: 26713839
    [Abstract] [Full Text] [Related]

  • 2. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
    Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, Rosenfeld RG, Zadik Z, Jaron-Mendelson M, Koren R, Amitzi L, Raduk D, Hershkovitz O, Hart G.
    J Clin Endocrinol Metab; 2017 May 01; 102(5):1578-1587. PubMed ID: 28323965
    [Abstract] [Full Text] [Related]

  • 3. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.
    Strasburger CJ, Vanuga P, Payer J, Pfeifer M, Popovic V, Bajnok L, Góth M, Olšovská V, Trejbalová L, Vadasz J, Fima E, Koren R, Amitzi L, Bidlingmaier M, Hershkovitz O, Hart G, Biller BMK.
    Eur J Endocrinol; 2017 Mar 01; 176(3):283-294. PubMed ID: 27932411
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children.
    Fisher DM, Rosenfeld RG, Jaron-Mendelson M, Amitzi L, Koren R, Hart G.
    Horm Res Paediatr; 2017 Mar 01; 87(5):324-332. PubMed ID: 28399519
    [Abstract] [Full Text] [Related]

  • 5. Designing a long-acting human growth hormone (hGH) by fusing the carboxyl-terminal peptide of human chorionic gonadotropin beta-subunit to the coding sequence of hGH.
    Fares F, Guy R, Bar-Ilan A, Felikman Y, Fima E.
    Endocrinology; 2010 Sep 01; 151(9):4410-7. PubMed ID: 20660071
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
    Kramer WG, Jaron-Mendelson M, Koren R, Hershkovitz O, Hart G.
    Clin Pharmacol Drug Dev; 2018 Jun 01; 7(5):554-563. PubMed ID: 29136343
    [Abstract] [Full Text] [Related]

  • 7. Comparative pharmacokinetics and pharmacodynamics of a PEGylated recombinant human growth hormone and daily recombinant human growth hormone in growth hormone-deficient children.
    Hou L, Chen ZH, Liu D, Cheng YG, Luo XP.
    Drug Des Devel Ther; 2016 Jun 01; 10():13-21. PubMed ID: 26719670
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics, Pharmacodynamics, and Efficacy of a Novel Long-Acting Human Growth Hormone: Fc Fusion Protein.
    Kim SJ, Kwak HH, Cho SY, Sohn YB, Park SW, Huh R, Kim J, Ko AR, Jin DK.
    Mol Pharm; 2015 Oct 05; 12(10):3759-65. PubMed ID: 26370910
    [Abstract] [Full Text] [Related]

  • 9. Albutropin: a growth hormone-albumin fusion with improved pharmacokinetics and pharmacodynamics in rats and monkeys.
    Osborn BL, Sekut L, Corcoran M, Poortman C, Sturm B, Chen G, Mather D, Lin HL, Parry TJ.
    Eur J Pharmacol; 2002 Dec 05; 456(1-3):149-58. PubMed ID: 12450581
    [Abstract] [Full Text] [Related]

  • 10. A novel long-acting human growth hormone fusion protein (VRS-317): enhanced in vivo potency and half-life.
    Cleland JL, Geething NC, Moore JA, Rogers BC, Spink BJ, Wang CW, Alters SE, Stemmer WP, Schellenberger V.
    J Pharm Sci; 2012 Aug 05; 101(8):2744-54. PubMed ID: 22678811
    [Abstract] [Full Text] [Related]

  • 11. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide.
    Langenheim JF, Chen WY.
    J Endocrinol; 2009 Dec 05; 203(3):375-87. PubMed ID: 19770179
    [Abstract] [Full Text] [Related]

  • 12. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: A reversible non-covalent albumin-binding growth hormone.
    Thygesen P, Andersen HS, Behrens C, Fels JJ, Nørskov-Lauritsen L, Rischel C, Johansen NL.
    Growth Horm IGF Res; 2017 Aug 05; 35():8-16. PubMed ID: 28595133
    [Abstract] [Full Text] [Related]

  • 13. Development and characterization of a novel long-acting recombinant follicle stimulating hormone agonist by fusing Fc to an FSH-β subunit.
    Zhang YL, Guo KP, Ji SY, Liu XM, Wang P, Wu J, Gao L, Jiang TQ, Xu T, Fan HY.
    Hum Reprod; 2016 Jan 05; 31(1):169-82. PubMed ID: 26621853
    [Abstract] [Full Text] [Related]

  • 14. Development of a sustained-release recombinant human growth hormone formulation.
    Kwak HH, Shim WS, Choi MK, Son MK, Kim YJ, Yang HC, Kim TH, Lee GI, Kim BM, Kang SH, Shim CK.
    J Control Release; 2009 Jul 20; 137(2):160-5. PubMed ID: 19332090
    [Abstract] [Full Text] [Related]

  • 15. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L, Luo XP, Du ML, Ma HM, Gong CX, Li YC, Shen SX, Zhao ZH, Liang L, Dong GP, Yan CY, Du HW.
    Zhonghua Er Ke Za Zhi; 2009 Jan 20; 47(1):48-52. PubMed ID: 19573383
    [Abstract] [Full Text] [Related]

  • 16. Fusing the carboxy-terminal peptide of the chorionic gonadotropin (CG) beta-subunit to the common alpha-subunit: retention of O-linked glycosylation and enhanced in vivo bioactivity of chimeric human CG.
    Furuhashi M, Shikone T, Fares FA, Sugahara T, Hsueh AJ, Boime I.
    Mol Endocrinol; 1995 Jan 20; 9(1):54-63. PubMed ID: 7539107
    [Abstract] [Full Text] [Related]

  • 17. A novel sustained-release formulation of recombinant human growth hormone and its pharmacokinetic, pharmacodynamic and safety profiles.
    Wei Y, Wang Y, Kang A, Wang W, Ho SV, Gao J, Ma G, Su Z.
    Mol Pharm; 2012 Jul 02; 9(7):2039-48. PubMed ID: 22663348
    [Abstract] [Full Text] [Related]

  • 18. Development of a novel sustained release formulation of recombinant human growth hormone using sodium hyaluronate microparticles.
    Kim SJ, Hahn SK, Kim MJ, Kim DH, Lee YP.
    J Control Release; 2005 May 18; 104(2):323-35. PubMed ID: 15907583
    [Abstract] [Full Text] [Related]

  • 19. Alterations of growth plate and abnormal insulin-like growth factor I metabolism in growth-retarded hypokalemic rats: effect of growth hormone treatment.
    Gil-Peña H, Garcia-Lopez E, Alvarez-Garcia O, Loredo V, Carbajo-Perez E, Ordoñez FA, Rodriguez-Suarez J, Santos F.
    Am J Physiol Renal Physiol; 2009 Sep 18; 297(3):F639-45. PubMed ID: 19587145
    [Abstract] [Full Text] [Related]

  • 20. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
    Rasmussen MH, Olsen MW, Alifrangis L, Klim S, Suntum M.
    J Clin Endocrinol Metab; 2014 Oct 18; 99(10):E1819-29. PubMed ID: 25013997
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.